RESUMEN
Food is the largest expense in fish farms. On the other hand, the fish health and wellbeing are determining factors in aquaculture production where nutrition is a vital process for growing animals. In fact, it is important to remember that digestion and nutrition are crucial for animals' physiology. However, digestion is a very complex process in which food is processed to obtain necessary nutrients and central mechanisms of this process require both endocrine and neuronal regulation. In this context, intestinal motility is essential for the absorption of the nutrients (digestive process determining nutrition). An imbalance in the intestinal motility due to an inadequate diet or an infectious process could result in a lower use of the food and inefficiency in obtaining nutrients from food. Very frequently, farmed fish are infected with different pathogenic microorganism and this situation could alter gastrointestinal physiology and, indirectly reduce fish growth. For these reasons, the present review focuses on analysing how different inflammatory molecules or infections can alter conventional modulators of fish intestinal motility.
Asunto(s)
Peces/inmunología , Motilidad Gastrointestinal/inmunología , Infecciones/veterinaria , Inflamación/veterinaria , Sistemas Neurosecretores/fisiopatología , Animales , Acuicultura , Digestión/fisiología , Fenómenos Fisiológicos del Sistema Digestivo , Enfermedades de los Peces/etiología , Enfermedades de los Peces/inmunología , Infecciones/etiología , Infecciones/inmunología , Inflamación/etiología , Inflamación/inmunología , Estado NutricionalAsunto(s)
Autoanticuerpos/metabolismo , Sistema Nervioso Entérico/patología , Enfermedades Gastrointestinales/patología , Motilidad Gastrointestinal/inmunología , Motilidad Gastrointestinal/fisiología , Autoanticuerpos/inmunología , Enfermedades Gastrointestinales/fisiopatología , Humanos , Intestino Delgado , NeuronasRESUMEN
Una mujer de 36 años, diagnosticada con síndrome de intestino irritable a predominio de diarrea (SII-D) acude a la consulta médica. Ella pregunta si el uso de probióticos sería útil para controlar los episodios de diarrea, ya que los fármacos con los que está siendo tratada no le resultan eficaces. Se realizó una búsqueda bibliográfica con el objetivo de en contrar evidencia en respuesta a su consulta, tras la cual se seleccionaron dos ensayos clínicos y una revisión sistemática. Se evidenciaron diversos resultados en cuanto al uso de probióticos en el SII-D y se discutieron los riesgos y beneficios del tratamiento, así como las implicancias en la vida de la paciente. (AU)
A 36-year-old woman diagnosed with diarrhea predominant irritable bowel syndrome (D-IBS) goes to meet the doctor. She raises whether the use of probiotics would be useful for controlling diarrhea episodes, since the drugs which she is being treated with, are not effective. A bibliographic search was conducted with the objective of finding evidence in response toher query. Two clinical trials and a systematic review were found. Variable results were found regarding the use of probioticsin D-IBS. The risks and benefits of the treatment were discussed, as well as the implications in the patient's lifestyle. (AU)
Asunto(s)
Humanos , Femenino , Adulto , Probióticos/uso terapéutico , Síndrome del Colon Irritable/terapia , Diarrea/terapia , Parasimpatolíticos/uso terapéutico , Calidad de Vida , Literatura de Revisión como Asunto , Dolor Abdominal/terapia , Resina de Colestiramina/uso terapéutico , Ensayos Clínicos como Asunto , Probióticos/administración & dosificación , Probióticos/efectos adversos , Síndrome del Colon Irritable/diagnóstico , Síndrome del Colon Irritable/etiología , Diarrea/complicaciones , Duración de la Terapia , Motilidad Gastrointestinal/inmunología , Mucosa Intestinal/inmunología , Loperamida/uso terapéutico , Antidepresivos/uso terapéuticoRESUMEN
Intestinal functions, including motility and secretion, are locally controlled by enteric neural networks housed within the wall of the gut. The fidelity of these functions depends on the precision of intercellular signaling among cellular elements, including enteric neurons, epithelial cells, immune cells, and glia, all of which are vulnerable to disruptive influences during inflammatory events. This review article describes current knowledge regarding inflammation-induced neuroplasticity along key elements of enteric neural circuits, what is known about the causes of these changes, and possible therapeutic targets for protecting and/or repairing the integrity of intrinsic enteric neurotransmission. Changes that have been detected in response to inflammation include increased epithelial serotonin availability, hyperexcitability of intrinsic primary afferent neurons, facilitation of synaptic activity among enteric neurons, and attenuated purinergic neuromuscular transmission. Dysfunctional propulsive motility has been detected in models of colitis, where causes include the changes described above, and in models of multiple sclerosis and other autoimmune conditions, where autoantibodies are thought to mediate dysmotility. Other cells implicated in inflammation-induced neuroplasticity include muscularis macrophages and enteric glia. Targeted treatments that are discussed include 5-hydroxytryptamine receptor 4 agonists, cyclooxygenase inhibitors, antioxidants, B cell depletion therapy, and activation of anti-inflammatory pathways.
Asunto(s)
Comunicación Celular/fisiología , Sistema Nervioso Entérico , Motilidad Gastrointestinal/inmunología , Inflamación , Plasticidad Neuronal/inmunología , Animales , Sistema Nervioso Entérico/inmunología , Sistema Nervioso Entérico/fisiopatología , Humanos , Inflamación/inmunología , Inflamación/fisiopatología , Inflamación/terapia , Enfermedad Autoinmune Experimental del Sistema NerviosoRESUMEN
Intestinal dysmotility is a frequent complication during sepsis and plays an important role in the development of secondary infections and multiple organ failure. However, the central mechanisms underlying this process have not been well elucidated. Currently, effective therapies are still lacking for the treatment of sepsis-induced intestinal dysmotility. In this study, we found that the activation of IL-17 signaling within the muscularis propria might be associated with dysmotility of the small intestine during polymicrobial sepsis. Furthermore, we demonstrated that targeting IL-17A partially rescued the motility of the small intestine and alleviated interstitial cells of Cajal (ICC) injury during sepsis. The blockade of IL-17A suppressed the dominant sepsis-induced infiltration of M1-polarized macrophages into the muscularis. Additionally, impaired ICC survival may be associated with the oxidative stress injury induced by dominant infiltration of M1-polarized macrophages. Our findings reveal the important role of the IL-17 signaling pathway in the small intestine during sepsis and provide clues for developing a novel therapeutic strategy for treating gastrointestinal dysmotility during sepsis.
Asunto(s)
Motilidad Gastrointestinal/inmunología , Interleucina-17/inmunología , Células Intersticiales de Cajal/inmunología , Intestino Delgado/inmunología , Sepsis/inmunología , Transducción de Señal/inmunología , Animales , Femenino , Interleucina-17/antagonistas & inhibidores , Células Intersticiales de Cajal/patología , Intestino Delgado/lesiones , Intestino Delgado/patología , Masculino , Ratones , Células RAW 264.7 , Sepsis/patologíaRESUMEN
BACKGROUND: Intestinal inflammation is the predominant contributor to the genesis of postoperative ileus. Janus kinase 1 plays an important role during inflammation. Here, we investigated the role of Janus kinase 1 in postoperative ileus and whether inhibition of Janus kinase 1 could mitigate postoperative ileus. METHODS: A mouse model of postoperative ileus was induced by intestinal manipulation. Janus kinase 1 inhibitor GLPG0634 or placebo was administered orally before intestinal manipulation. At the indicated time points post operation, neutrophil infiltration was assessed by immunohistochemistry and enzyme-linked immunosorbent assay; proinflammatory gene expression was quantified by quantitative reverse-transcriptase polymerase chain reaction and enzyme-linked immunosorbent assay; and Janus kinase 1 activation was detected by Western blot. Functional studies were conducted to evaluate intestinal motility. RESULTS: We found that intestinal manipulation led to marked activation of Janus kinase 1, with increased proinflammatory gene expression and upregulated myeloperoxidase level. Moreover, intestinal manipulation resulted in an impairment of intestinal transit in vivo and inhibition of smooth muscle contractility in vitro. Preoperative administration of GLPG0634 markedly lowered the expression of proinflammatory cytokines, the myeloperoxidase level in the muscularis layer after bowel manipulation, and significantly ameliorated smooth muscle contractile function and intestinal transit ability. CONCLUSION: Our data showed that Janus kinase 1 activation mediated intestinal manipulation-induced resident macrophage activation after intestinal manipulation, and subsequent complex inflammatory cascade and gut dysmotility. Janus kinase 1 inhibition appears to be a prospective and convenient approach for the prevention of postoperative ileus.
Asunto(s)
Ileus/prevención & control , Janus Quinasa 1/antagonistas & inhibidores , Yeyuno/cirugía , Complicaciones Posoperatorias/prevención & control , Piridinas/administración & dosificación , Triazoles/administración & dosificación , Animales , Modelos Animales de Enfermedad , Motilidad Gastrointestinal/efectos de los fármacos , Motilidad Gastrointestinal/inmunología , Humanos , Ileus/etiología , Mediadores de Inflamación/metabolismo , Mucosa Intestinal/efectos de los fármacos , Mucosa Intestinal/inmunología , Mucosa Intestinal/cirugía , Janus Quinasa 1/metabolismo , Yeyuno/efectos de los fármacos , Yeyuno/inmunología , Masculino , Ratones , Contracción Muscular/efectos de los fármacos , Contracción Muscular/inmunología , Músculo Liso/efectos de los fármacos , Músculo Liso/inmunología , Peroxidasa/metabolismo , Complicaciones Posoperatorias/etiología , Cuidados Preoperatorios/métodos , Transducción de Señal/efectos de los fármacos , Transducción de Señal/inmunología , Regulación hacia Arriba/efectos de los fármacosRESUMEN
Estrogens play important roles in the development and progression of multiple tumor types. Accumulating evidence points to the significance of estrogen action not only in tumors of hormonally regulated tissues such as the breast, endometrium and ovary, but also in the development of colorectal cancer (CRC). The effects of estrogens in physiological and pathophysiological conditions are mediated by the nuclear estrogen receptors α and ß, as well as the membrane-bound G protein-coupled estrogen receptor (GPER). The roles of GPER in CRC development and progression, however, remain poorly understood. Studies on the functions of GPER in the colon have shown that this estrogen receptor regulates colonic motility as well as immune responses in CRC-associated diseases, such as Crohn's disease and ulcerative colitis. GPER is also involved in cell cycle regulation, endoplasmic reticulum stress, proliferation, apoptosis, vascularization, cell migration, and the regulation of fatty acid and estrogen metabolism in CRC cells. Thus, multiple lines of evidence suggest that GPER may play an important role in colorectal carcinogenesis. In this review, we present the current state of knowledge regarding the contribution of GPER to colon function and CRC.
Asunto(s)
Colitis Ulcerosa/patología , Colon/fisiopatología , Neoplasias Colorrectales/patología , Enfermedad de Crohn/patología , Receptores de Estrógenos/metabolismo , Receptores Acoplados a Proteínas G/metabolismo , Animales , Carcinogénesis/inmunología , Carcinogénesis/patología , Colitis Ulcerosa/inmunología , Colitis Ulcerosa/fisiopatología , Colon/inmunología , Colon/patología , Neoplasias Colorrectales/inmunología , Enfermedad de Crohn/inmunología , Enfermedad de Crohn/fisiopatología , Modelos Animales de Enfermedad , Progresión de la Enfermedad , Estrógenos/metabolismo , Motilidad Gastrointestinal/inmunología , Humanos , Mucosa Intestinal/inmunología , Mucosa Intestinal/patología , Mucosa Intestinal/fisiopatologíaRESUMEN
BACKGROUND: Irritable bowel syndrome (IBS) is a common chronic non-organic disease of the digestive system. Berberine (BBR) has been used to treat patients with IBS, but the underlying therapeutic mechanism is little understood. We believe that BBR achieves its therapeutic effect on IBS by preventing stress intestinal inflammation and visceral hypersensitivity and reducing bowel motility. AIM: To test the hypothesis that BBR achieves its therapeutic effect on IBS by preventing subclinical inflammation of the intestinal mucosa and reducing visceral hypersensitivity and intestinal motility. METHODS: IBS was induced in rats via water avoidance stress (WAS). qRT-PCR and histological analyses were used to evaluate the levels of cytokines and mucosal inflammation, respectively. Modified ELISA and qRT-PCR were used to evaluate the nuclear factor kappa-B (NF-κB) signal transduction pathway. Colorectal distention test, gastrointestinal transit measurement, Western blot, and qRT-PCR were used to analyze visceral sensitivity, intestinal motility, the expression of C-kit (marker of Cajal mesenchymal cells), and the expression of brain derived neurotrophic factor (BDNF) and its receptor TrkB. RESULTS: WAS led to mucosal inflammation, visceral hyperalgesia, and high intestinal motility. Oral administration of BBR inhibited the NF-κB signal transduction pathway, reduced the expression of pro-inflammatory cytokines [interleukin (IL)-1ß, IL-6, interferon-γ, and tumor necrosis factor-α], promoted the expression of anti-inflammatory cytokines (IL-10 and transforming growth factor-ß), and improved the terminal ileum tissue inflammation. BBR inhibited the expression of BDNF, TrkB, and C-kit in IBS rats, leading to the reduction of intestinal motility and visceral hypersensitivity. The therapeutic effect of BBR at a high dose (100 mg/kg) was superior to than that of the low-dose (25 mg/kg) group. CONCLUSION: BBR reduces intestinal mucosal inflammation by inhibiting the intestinal NF-κB signal pathway in the IBS rats. BBR reduces the expression of BDNF, its receptor TrkB, and C-kit. BBR also reduces intestinal motility and visceral sensitivity to achieve its therapeutic effect on IBS.
Asunto(s)
Berberina/farmacología , Sistema Nervioso Entérico/efectos de los fármacos , Hiperalgesia/tratamiento farmacológico , Síndrome del Colon Irritable/tratamiento farmacológico , Estrés Psicológico/complicaciones , Animales , Berberina/uso terapéutico , Citocinas/inmunología , Citocinas/metabolismo , Modelos Animales de Enfermedad , Sistema Nervioso Entérico/fisiopatología , Motilidad Gastrointestinal/efectos de los fármacos , Motilidad Gastrointestinal/inmunología , Humanos , Hiperalgesia/fisiopatología , Hiperalgesia/psicología , Mucosa Intestinal/efectos de los fármacos , Mucosa Intestinal/inmunología , Mucosa Intestinal/inervación , Síndrome del Colon Irritable/inmunología , Síndrome del Colon Irritable/psicología , Masculino , Ratas , Estrés Psicológico/psicología , Resultado del TratamientoRESUMEN
Inflammatory bowel diseases frequently cause gastrointestinal dysmotility, suggesting that they may also affect the enteric nervous system. So far, the precise mechanisms that lead to gastrointestinal dysmotility in inflammatory bowel diseases have not been elucidated. To determine the effect of CD8 T cells on gastrointestinal motility, transgenic mice expressing ovalbumin on enteric neurons were generated. In these mice, adoptive transfer of ovalbumin-specific OT-I CD8 T cells induced severe enteric ganglionitis. CD8 T cells homed to submucosal and myenteric plexus neurons, 60% of which were lost, clinically resulting in severely impaired gastrointestinal transition. Anti-interferon-γ treatment rescued neurons by preventing their up-regulation of major histocompatibility complex class I antigen, thus preserving gut motility. These preclinical murine data translated well into human gastrointestinal dysmotility. In a series of 30 colonic biopsy specimens from patients with gastrointestinal dysmotility, CD8 T cell-mediated ganglionitis was detected that was followed by severe loss of enteric neurons (74.8%). Together, the preclinical and clinical data support the concept that autoimmune CD8 T cells play an important pathogenetic role in gastrointestinal dysmotility and may destroy enteric neurons.
Asunto(s)
Enfermedades Autoinmunes/inmunología , Linfocitos T CD8-positivos/inmunología , Motilidad Gastrointestinal/inmunología , Enfermedades Inflamatorias del Intestino/inmunología , Plexo Mientérico/inmunología , Animales , Enfermedades Autoinmunes/genética , Enfermedades Autoinmunes/patología , Linfocitos T CD8-positivos/patología , Motilidad Gastrointestinal/genética , Humanos , Enfermedades Inflamatorias del Intestino/genética , Enfermedades Inflamatorias del Intestino/patología , Ratones , Ratones Transgénicos , Plexo Mientérico/patologíaRESUMEN
Objective: Postoperative ileus (POI) is an inflammation-mediated complication of abdominal surgery, characterized by intestinal dysmotility and leukocyte infiltration into the muscularis externa (ME). Previous studies indicated that interleukin (IL)-10 is crucial for the resolution of a variety of inflammation-driven diseases. Herein, we investigated how IL-10 affects the postoperative ME inflammation and found an unforeseen role of IL-10 in POI. Design: POI was induced by a standardized intestinal manipulation (IM) in C57BL/6 and multiple transgenic mouse strain including C-C motif chemokine receptor 2-/-, IL-10-/-, and LysMcre/IL-10fl/fl mice. Leukocyte infiltration, gene and protein expression of cytokines, chemokines, and macrophage differentiation markers as well as intestinal motility were analyzed. IL-10 serum levels in surgical patients were determined by ELISA. Results: IL-10 serum levels were increased in patient after abdominal surgery. In mice, a complete or leucocyte-restricted IL-10 deficiency ameliorated POI and reduced the postoperative ME neutrophil infiltration. Infiltrating monocytes were identified as main IL-10 producers and undergo IL-10-dependent M2 polarization. Interestingly, M2 polarization is not crucial to POI development as abrogation of monocyte infiltration did not prevent POI due to a compensation of the IL-10 loss by resident macrophages and neutrophils. Organ culture studies demonstrated that IL-10 deficiency impeded neutrophil migration toward the surgically traumatized ME. This mechanism is mediated by reduction of neutrophil attracting chemokines. Conclusion: Monocyte-derived macrophages are the major IL-10 source during POI. An IL-10 deficiency decreases the postoperative expression of neutrophil-recruiting chemokines, consequently reduces the neutrophil extravasation into the postsurgical bowel wall, and finally protects mice from POI.
Asunto(s)
Ileus/inmunología , Interleucina-10/inmunología , Intestinos/inmunología , Leucocitos/inmunología , Complicaciones Posoperatorias/inmunología , Animales , Modelos Animales de Enfermedad , Motilidad Gastrointestinal/inmunología , Humanos , Inflamación/inmunología , Macrófagos/inmunología , Masculino , Ratones , Ratones Endogámicos C57BL , Ratones Transgénicos/inmunología , Monocitos/inmunología , Infiltración Neutrófila/inmunología , Neutrófilos/inmunología , Periodo PosoperatorioRESUMEN
Macrophages are highly heterogeneous tissue-resident immune cells that perform a variety of tissue-supportive functions. The current paradigm dictates that intestinal macrophages are continuously replaced by incoming monocytes that acquire a pro-inflammatory or tissue-protective signature. Here, we identify a self-maintaining population of macrophages that arise from both embryonic precursors and adult bone marrow-derived monocytes and persists throughout adulthood. Gene expression and imaging studies of self-maintaining macrophages revealed distinct transcriptional profiles that reflect their unique localization (i.e., closely positioned to blood vessels, submucosal and myenteric plexus, Paneth cells, and Peyer's patches). Depletion of self-maintaining macrophages resulted in morphological abnormalities in the submucosal vasculature and loss of enteric neurons, leading to vascular leakage, impaired secretion, and reduced intestinal motility. These results provide critical insights in intestinal macrophage heterogeneity and demonstrate the strategic role of self-maintaining macrophages in gut homeostasis and intestinal physiology.
Asunto(s)
Intestinos/inmunología , Macrófagos/inmunología , Animales , Tipificación del Cuerpo/fisiología , Diferenciación Celular/genética , Diferenciación Celular/inmunología , Motilidad Gastrointestinal/inmunología , Motilidad Gastrointestinal/fisiología , Homeostasis , Inflamación/inmunología , Mucosa Intestinal/inmunología , Intestino Delgado/metabolismo , Ratones , Monocitos/metabolismo , Neuronas/metabolismo , Fagocitos/inmunología , TranscriptomaAsunto(s)
Diarrea/terapia , Intolerancia a la Lactosa/prevención & control , Oncología Médica/normas , Neoplasias/terapia , Cuidados Paliativos/normas , Adulto , Factores de Edad , Anciano , Analgésicos Opioides/efectos adversos , Protocolos de Quimioterapia Combinada Antineoplásica/efectos adversos , Biomarcadores/análisis , Dolor en Cáncer/tratamiento farmacológico , Dolor en Cáncer/etiología , Diarrea/diagnóstico , Diarrea/etiología , Diarrea/psicología , Dietoterapia/métodos , Dietoterapia/normas , Europa (Continente) , Excipientes/efectos adversos , Motilidad Gastrointestinal/efectos de los fármacos , Motilidad Gastrointestinal/genética , Motilidad Gastrointestinal/inmunología , Motilidad Gastrointestinal/efectos de la radiación , Humanos , Lactosa/efectos adversos , Intolerancia a la Lactosa/complicaciones , Intolerancia a la Lactosa/diagnóstico , Intolerancia a la Lactosa/etiología , Anamnesis , Oncología Médica/métodos , Estadificación de Neoplasias , Neoplasias/sangre , Neoplasias/complicaciones , Cuidados Paliativos/métodos , Medicina de Precisión/métodos , Medicina de Precisión/normas , Autocuidado/métodos , Autocuidado/normas , Sociedades Médicas/normas , Procedimientos Quirúrgicos Operativos/efectos adversosRESUMEN
BACKGROUND: The existence of several autoantibodies suggests an autoimmune basis for gastrointestinal (GI) dysmotility. Whether GI motility disorders are features of autoimmune autonomic ganglionopathy (AAG) or are related to circulating anti-ganglionic acetylcholine receptor (gAChR) antibodies (Abs) is not known. The aim of this study was to determine the associations between autonomic dysfunction, anti-gAChR Abs, and clinical features in patients with GI motility disorders including achalasia and chronic intestinal pseudo-obstruction (CIPO). METHODS: First study: retrospective cohort study and laboratory investigation. Samples from 123 patients with seropositive AAG were obtained between 2012 and 2017. Second study: prospective study. Samples from 28 patients with achalasia and 14 patients with CIPO were obtained between 2014 and 2016, and 2013 and 2017, respectively. In the first study, we analyzed clinical profiles of seropositive AAG patients. In the second study, we compared clinical profiles, autonomic symptoms, and results of antibody screening between seropositive, seronegative achalasia, and CIPO groups. RESULTS: In the first study, we identified 10 patients (8.1%) who presented with achalasia, or gastroparesis, or paralytic ileus. In the second study, we detected anti-gAChR Abs in 21.4% of the achalasia patients, and in 50.0% of the CIPO patients. Although patients with achalasia and CIPO demonstrated widespread autonomic dysfunction, bladder dysfunction was observed in the seropositive patients with CIPO as a prominent clinical characteristic of dysautonomia. CONCLUSIONS: These results demonstrate a significant prevalence of anti-gAChR antibodies in patients with achalasia and CIPO. Anti-gAChR Abs might mediate autonomic dysfunction, contributing to autoimmune mechanisms underlying these GI motility disorders.
Asunto(s)
Enfermedades Autoinmunes/inmunología , Enfermedades del Sistema Nervioso Autónomo/inmunología , Enfermedades Gastrointestinales/inmunología , Motilidad Gastrointestinal/inmunología , Adulto , Anciano , Anciano de 80 o más Años , Autoanticuerpos/inmunología , Enfermedades Autoinmunes/fisiopatología , Enfermedades del Sistema Nervioso Autónomo/fisiopatología , Niño , Enfermedad Crónica , Estudios de Cohortes , Acalasia del Esófago/inmunología , Acalasia del Esófago/fisiopatología , Femenino , Ganglios Autónomos/inmunología , Enfermedades Gastrointestinales/fisiopatología , Humanos , Seudoobstrucción Intestinal/inmunología , Seudoobstrucción Intestinal/fisiopatología , Japón , Masculino , Persona de Mediana Edad , Estudios Prospectivos , Receptores Colinérgicos/inmunología , Estudios RetrospectivosRESUMEN
BACKGROUND: Multiple sclerosis (MS) is an autoimmune disease of the central nervous system that, in addition to motor, sensory, and cognitive symptoms, also causes constipation, which is poorly understood. Here, we characterize gastrointestinal (GI) dysmotility in the experimental autoimmune encephalomyelitis (EAE) mouse model of MS and evaluate whether autoantibodies target the enteric nervous system (ENS) and cause dysmotility. METHODS: EAE was induced in male SJL and B6 mice. GI motility was assessed in vivo and ex vivo in wild type (WT) and B cell-deficient mice. MS and EAE serum was used to survey potential targets in the ENS and changes in the ENS structure were characterized using immunohistochemistry. KEY RESULTS: EAE mice developed accelerated gastric emptying and delayed whole GI transit with reduced colonic motility. Fecal water content was reduced, and colonic migrating myoelectrical complexes (CMMC) and slow waves were less frequent. Colons from EAE mice exhibited decreased GFAP levels in glia. Sera from MS patients and from EAE mice targeted ENS neurons and glia. B-cell deficiency in EAE protected against colonic dysmotility. CONCLUSIONS & INFERENCES: Consistent with symptoms experienced in MS, we demonstrate that EAE mice widely exhibit features of GI dysmotility that persisted in the absence of extrinsic innervation, suggesting direct involvement of ENS neurocircuitry. The absence of GI dysmotility in B cell-deficient mice with EAE together with EAE and MS serum immunoreactivity against ENS targets suggests that MS could be classified among other diseases known to induce autoimmune GI dysmotility.
Asunto(s)
Autoanticuerpos/inmunología , Estreñimiento/inmunología , Encefalomielitis Autoinmune Experimental/complicaciones , Encefalomielitis Autoinmune Experimental/inmunología , Motilidad Gastrointestinal/inmunología , Animales , Sistema Nervioso Entérico/inmunología , Humanos , Masculino , Ratones , Ratones Endogámicos C57BL , Esclerosis Múltiple/complicaciones , Esclerosis Múltiple/inmunología , Neuroglía/inmunología , Neuronas/inmunologíaRESUMEN
In this study, we investigated the role of transient receptor potential melastatin 2 (TRPM2), a nonselective cation channel abundantly expressed in inflammatory cells such as macrophages, in the development of postoperative ileus, a complication of abdominal surgery characterized by gastrointestinal dysmotility. In wild-type mice, we found that intestinal manipulation, a maneuver that elicits symptoms typical of postoperative ileus, delays the transit of fluorescein-labeled dextran, promotes the infiltration of CD68+ macrophages, Ly6B.2+ neutrophils, and MPO+ cells into intestinal muscles, boosts expression of IL-1ß, IL-6, TNF-α, iNOS, and CXCL2 in intestinal muscles and peritoneal macrophages, enhances phosphorylation of ERK and p38 MAPK in intestinal muscles, and amplifies IL-1ß, IL-6, TNF-α, iNOS, and CXCL2 expression in resident and thioglycolate-elicited peritoneal macrophages following exposure to lipopolysaccharide. Remarkably, TRPM2 deficiency completely blocks or diminishes these effects. Indeed, intestinal manipulation appears to activate TRPM2 in resident muscularis macrophages and elicits release of inflammatory cytokines and chemokines, which, in turn, promote infiltration of macrophages and neutrophils into the muscle, ultimately resulting in dysmotility. NEW & NOTEWORTHY Activation of transient receptor potential melastatin 2 (TRPM2) releases inflammatory cytokines and chemokines, which, in turn, promote the infiltration of inflammatory cells and macrophages into intestinal muscles, ultimately resulting in dysmotility. Thus TRPM2 is a promising target in treating dysmotility due to postoperative ileus, a complication of abdominal surgery.
Asunto(s)
Motilidad Gastrointestinal/inmunología , Ileus , Laparotomía/efectos adversos , Complicaciones Posoperatorias/inmunología , Canales Catiónicos TRPM/metabolismo , Animales , Quimiocina CXCL2/metabolismo , Modelos Animales de Enfermedad , Ileus/etiología , Ileus/inmunología , Inflamación/metabolismo , Interleucina-1beta/metabolismo , Macrófagos Peritoneales/metabolismo , Ratones , Músculo Liso/metabolismo , Neutrófilos/metabolismo , Canales Catiónicos TRPC/metabolismoRESUMEN
Macrophages residing in the muscularis externa of the gastrointestinal tract are highly specialized cells that are essential for tissue homeostasis during steady-state conditions as well as during disease. They are characterized by their unique protective functional phenotype that is undoubtedly a consequence of the reciprocal interaction with their environment, including the enteric nervous system. This muscularis macrophage-neuron interaction dictates intestinal motility and promotes tissue-protection during injury and infection, but can also contribute to tissue damage in gastrointestinal disorders such as post-operative ileus and gastroparesis. Although the importance of muscularis macrophages is clearly recognized, different aspects of these cells remain largely unexplored such their origin, longevity and instructive signals that determine their function and phenotype. In this review, we will discuss the phenotype, functions and origin of muscularis macrophages during steady-state and disease conditions. We will highlight the bidirectional crosstalk with neurons and potential therapeutic strategies that target and manipulate muscularis macrophages to restore their protective signature as a treatment for disease.
Asunto(s)
Homeostasis/inmunología , Enfermedades Intestinales/inmunología , Intestinos/inmunología , Macrófagos/inmunología , Músculo Liso/inmunología , Animales , Sistema Nervioso Entérico/inmunología , Motilidad Gastrointestinal/inmunología , Humanos , Intestinos/inervación , Músculo Liso/citología , Músculo Liso/inervación , Neuronas/inmunologíaRESUMEN
When related to central nervous system (CNS) health and disease, brain mast cells (MCs) can be a source of either beneficial or deleterious signals acting on neural cells. We review the current state of knowledge about molecular interactions between MCs and glia in neurodegenerative diseases such as Multiple Sclerosis, Alzheimer's disease, Amyotrophic Lateral Sclerosis, Parkinson's disease, Epilepsy. We also discuss the influence on MC actions evoked by the host microbiota, which has a profound effect on the host immune system, inducing important consequences in neurodegenerative disorders. Gut dysbiosis, reduced intestinal motility and increased intestinal permeability, that allow bacterial products to circulate and pass through the blood-brain barrier, are associated with neurodegenerative disease. There are differences between the microbiota of neurologic patients and healthy controls. Distinguishing between cause and effect is a challenging task, and the molecular mechanisms whereby remote gut microbiota can alter the brain have not been fully elucidated. Nevertheless, modulation of the microbiota and MC activation have been shown to promote neuroprotection. We review this new information contributing to a greater understanding of MC-microbiota-neural cells interactions modulating the brain, behavior and neurodegenerative processes.
Asunto(s)
Mastocitos/inmunología , Mastocitos/fisiología , Enfermedades Neurodegenerativas/inmunología , Barrera Hematoencefálica/inmunología , Barrera Hematoencefálica/microbiología , Barrera Hematoencefálica/fisiología , Encéfalo/inmunología , Comunicación Celular , Permeabilidad de la Membrana Celular/inmunología , Sistema Nervioso Central/inmunología , Microbioma Gastrointestinal/inmunología , Microbioma Gastrointestinal/fisiología , Motilidad Gastrointestinal/inmunología , Humanos , Intestinos/microbiología , Mastocitos/microbiología , Microbiota , Enfermedades Neurodegenerativas/microbiología , Neuroglía/inmunologíaRESUMEN
Inflammation plays a role in abdominal surgery (AS)-induced intestinal ileus that is alleviated by electrical vagal stimulation. Intracisternal injection of RX-77368, the stable thyrotropin-releasing hormone agonist, activates dorsal motor nucleus neurons and gastric vagal efferent discharges. We investigated the gastric inflammation induced by AS and the modulation by intracisternal RX-77368 in rats. RX-77368 (50 ng/rat) or saline was injected followed, 1 h later, by laparotomy and small intestinal/cecal manipulation. The sham group had anesthesia alone. After 6 h, gastric emptying (GE) and the inflammation in gastric corpus were determined. AS inhibited GE by 72% vs. control and doubled the number of M1-like macrophage immunoreactive for major histocompatibility complex class II (MHCII; M1 marker) but not for cluster of differentiation 206 (CD206; M2 marker) (MHCII+/CD206-) while there was no change in M2-like macrophages (MHCII-/CD206+). AS increased mRNA levels of interleukin-1ß (IL-1ß) and tumor necrosis factor α (TNF-α) by 1.7- and 1.5-fold, respectively, in the gastric submucosa plus muscle layers and the infiltration of neutrophils labeled by myeloperoxidase by 9.5-fold in the muscularis externa. RX-77368 inhibited AS-related gastric changes while not altering these parameters in the sham group. There was a significant negative correlation between GE and IL-1ß (r = -0.46), TNF-α (r = -0.44), M1 macrophage (r = -0.82), and neutrophils (r = -0.91). The M2-like macrophages and IL-10 expression were unchanged by AS with intracisternal saline or RX-77368. These data indicate that AS activates gastric M1 macrophages and increases proinflammatory cytokines expression, which are prevented by central vagal activation and may contribute to the correlated dampening of postoperative gastric ileus.NEW & NOTEWORTHY MHCII+/CD206- (M1) and MHCII-/CD206+ (M2) constitute two distinct populations of macrophages that are in close apposition to the cholinergic neurons in the rat gastric myenteric plexus (MP). Abdominal surgery (6 h) activates M1 macrophage leading to inflammation in the gastric MP correlated with the delayed gastric emptying, which was abolished by central vagal stimulation via intracisternal injection of RX-77368. Vagal stimulation linked with the cephalic phase may have potential beneficial effects to curtail postoperative gastric ileus.
Asunto(s)
Enterostomía/efectos adversos , Motilidad Gastrointestinal/inmunología , Seudoobstrucción Intestinal/inmunología , Seudoobstrucción Intestinal/prevención & control , Activación de Macrófagos/inmunología , Plexo Mientérico/fisiopatología , Nervio Vago/fisiopatología , Animales , Motilidad Gastrointestinal/efectos de los fármacos , Seudoobstrucción Intestinal/etiología , Activación de Macrófagos/efectos de los fármacos , Masculino , Plexo Mientérico/efectos de los fármacos , Complejo Mioeléctrico Migratorio/efectos de los fármacos , Complejo Mioeléctrico Migratorio/inmunología , Ácido Pirrolidona Carboxílico/administración & dosificación , Ácido Pirrolidona Carboxílico/análogos & derivados , Ratas , Ratas Sprague-Dawley , Hormona Liberadora de Tirotropina/administración & dosificación , Hormona Liberadora de Tirotropina/análogos & derivados , Resultado del Tratamiento , Nervio Vago/efectos de los fármacosRESUMEN
OBJECTIVES: Currently, probiotics are increasingly used as the alternative to antibiotics as well as the preventive measures in humans. In particular, probiotics occupy a key position in the treatment of antibiotics-associated intestinal dysbiosis. A spore-forming microorganism lactobacillus Bacillus coagulans is one of the most promising probiotics. However, some of its pharmacological effects remain poorly understood. This study was aimed at investigation of the effect of B. coagulans (Laktovit Forte) on the intestinal dysbiosis syndrome in mice caused by streptomycin against the background of cyclophosphamide-induced cellular immunodeficiency. METHODS: Pharmacological method: mouse model in vivo with immunodeficiency caused by cyclophosphamide. KEY FINDINGS: In mice with colitis caused by streptomycin treatment, the administration of B. coagulans (Laktovit Forte medicinal product) resulted in an antidiarrhoeal effect, normalisation of gastrointestinal motility and prevention of the animals' weight loss. Given the cyclophosphamide-induced immunosuppression and streptomycin-associated diarrhoea, the immunity was completely restored only under the action of B. coagulans. CONCLUSIONS: According to all parameters, B. coagulans has been proved to be more effective as compared to the Linex Forte reference product containing lacto- and bifidobacteria.
Asunto(s)
Bacillus coagulans/inmunología , Enterocolitis Seudomembranosa/inmunología , Probióticos/uso terapéutico , Animales , Antidiarreicos/farmacología , Antidiarreicos/uso terapéutico , Citocinas/antagonistas & inhibidores , Citocinas/inmunología , Enterocolitis Seudomembranosa/inducido químicamente , Enterocolitis Seudomembranosa/tratamiento farmacológico , Motilidad Gastrointestinal/efectos de los fármacos , Motilidad Gastrointestinal/inmunología , Macrófagos Peritoneales/efectos de los fármacos , Macrófagos Peritoneales/inmunología , Masculino , Ratones , Probióticos/farmacología , Estreptomicina/toxicidadRESUMEN
Studying the mechanisms of the small intestine motor function disorders during endotoxemia and searching ways to mitigate them remain relevant. The article discusses the role of inflammatory mediators, in particular nitric oxide as a key factor in the generation of inflammatory response and brake the main neurotransmitter in the gut in the pathogenesis of the small intestine motor disorders during endotoxemia. Also discusses anti-inflammatory cholinergic path, which is realized with the participation of the autonomic nervous system. Possible mechanisms by which tributyrinte as a component of nutritional support creates a multiplier effect in arresting the inflammatory response and normalization of intestinal motility are suggested.